⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863374 | 1.00 | — | — | |
| SCHEMBL15134735 | 1.00 | — | — | |
| SCHEMBL8245418 | 0.90 | — | — | |
| SCHEMBL11942459 | 0.90 | — | — | |
| SCHEMBL13686684 | 0.90 | — | — | |
| Cyclohexene SCHEMBL11017505 | 0.85 | — | — | |
| SCHEMBL27725254 | 0.77 | CYP2D6 (0.35) | — | |
| SCHEMBL24111503 | 0.75 | — | — | |
| SCHEMBL1484812 | 0.75 | — | — | |
| SCHEMBL899412 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232531-B | Preparation method of cabitinib | 安庆奇创药业有限公司 | 2020-06-16 | — | — | CN | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| WO-2024096753-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023141866-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | WO | disclosed |
| US-20230135772-A1 | CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4130154-A1 | CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT | Asahi Kasei Kabushiki Kaisha (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115190901-A | Carbodiimide composition, curing agent composition, coating composition, and resin cured product | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022193871-A1 | PREPARATION AND USE OF KRASG12D MUTANT PROTEIN INHIBITOR | 药雅科技(上海)有限公司 | 2022-09-22 | — | — | WO | disclosed |
| WO-2022000031-A1 | NOVEL COMPOUNDS | Pakinax Pty Ltd (AU) | 2022-01-06 | — | — | WO | disclosed |
| WO-2012083053-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011156775-A2 | 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156640-A2 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156786-A2 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2009012280-A2 | BENZIMIDAZOLE POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |